The End of Hepatitis C

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 4, 2014, Pages 533-536

  Sussman, Norman L ^a   Remien, Christopher H ^b   Kanwal, Fasiha ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANTIVIRAL THERAPY; DISEASE ELIMINATION; DRUG APPROVAL; DRUG COST; DRUG RESPONSE; EDITORIAL; EPIDEMIC; ERADICATION THERAPY; HEALTH CARE UTILIZATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; MONOTHERAPY; MORTALITY; NONHUMAN; POLIOMYELITIS; PREDICTIVE VALUE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALLPOX; UNITED STATES; VACCINATION; VIRUS TRANSMISSION;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; DISEASE ERADICATION; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; UNITED STATES;

EID: 84896077232     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.01.025     Document Type: Editorial

References (37)

1. Chak E., Talal A.H., Sherman K.E., et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011, 31:1090-1101.
2. Naggie S. Management of hepatitis C virus infection: the basics. Top Antivir Med 2012, 20:154-161.
3. Lee M.H., Yang H.I., Lu S.N., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. JInfect Dis 2012, 206:469-477.
4. Gordon S.C., Pockros P.J., Terrault N.A., et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012, 56:1651-1660.
5. El Khoury A.C., Vietri J., Prajapati G. The burden of untreated hepatitis C virus infection: a US patients' perspective. Dig Dis Sci 2012, 57:2995-3003.
6. Backus L.I., Boothroyd D.B., Phillips B.R., et al. Asustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9:509-516.
7. Cardoso A.C., Moucari R., Figueiredo-Mendes C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. JHepatol 2010, 52:652-657.
8. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. NEngl J Med 2011, 365:1014-1024.
9. Mahale P., Okhuysen P.C., Torres H.A. Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?. Clin Gastroenterol Hepatol 2013, Nov 7. Epub ahead of print.
10. Manns M.P., Pockros P.J., Norkrans G., et al. Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin. JViral Hepat 2013, 20:524-529.
11. Swain M.G., Lai M.Y., Shiffman M.L., et al. Asustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010, 139:1593-1601.
12. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. NEngl J Med 2013, 368:1878-1887.
13. Jesudian A.B., de Jong Y.P., Jacobson I.M. Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol 2013, 11:612-619.
14. Schmidt W.N., Nelson D.R., Pawlotsky J.M., et al. Direct acting antiviral agents and the path to interferon independence. ClinGastroenterol Hepatol 2013, Jul 18. Epub ahead of print.
15. Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. NEngl J Med 2014, 370:211-221.
16. Kowdley K.V., Lawitz E., Poordad F., et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. NEngl J Med 2014, 370:222-232.
17. Barquet N., Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann Intern Med 1997, 127(Pt 1):635-642.
18. Rodriguez-Alvarez M., Jimenez-Corona M.E., Cervantes-Rosales R., et al. Polio eradication: how long and how much to the end?. Arch Med Res 2013, 44:401-404.
19. Luo H.M., Zhang Y., Wang X.Q., et al. Identification and control of a poliomyelitis outbreak in Xinjiang, China. NEngl J Med 2013, 369:1981-1990.
20. Mundel T., Orenstein W.A. No country is safe without global eradication of poliomyelitis. NEngl J Med 2013, 369:2045-2046.
21. Alter H.J. To have B or not to have B: vaccine and the potential eradication of hepatitis B. JHepatol 2012, 57:715-717.
22. Ni Y.H., Chang M.H., Wu J.F., et al. Minimization of hepatitis B infection by a 25-year universal vaccination program. JHepatol 2012, 57:730-735.
23. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep 2011, 60:1618-1623. Centers for Disease Control and Prevention.
24. Raymond H.F., Chen Y.H., Ick T., et al. Anew trend in the HIV epidemic among men who have sex with men, San Francisco, 2004-2011. JAcquir Immune Defic Syndr 2013, 62:584-589.
25. Das M., Chu P.L., Santos G.M., et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010, 5:11068.
26. Das M., Raymond H.F., Chu P., et al. Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from National HIV Behavioral Surveillance, 2004-2011. JAcquir Immune Defic Syndr 2013, 63:e84-e86.
27. Kanwal F., Lok A.S., El-Serag H.B. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol 2013, 11:200-203.
28. Kanwal F., Lok A.S., El-Serag H.B. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Gastroenterology 2013, 144:478-481.
29. Aronsohn A., Jensen D. Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy. Hepatology 2014, 59:13-15.
30. Arora S., Thornton K., Komaromy M., et al. Demonopolizing medical knowledge. Acad Med 2014, 89:30-32.
31. Arora S., Thornton K., Murata G., et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. NEngl J Med 2011, 364:2199-2207.
32. Bate J.P., Colman A.J., Frost P.J., et al. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. JGastroenterol Hepatol 2010, 25:1276-1280.
33. Hagan L.M., Schinazi R.F. Best strategies for global HCV eradication. Liver Int 2013, 33(Suppl 1):68-79.
34. Morris K. Calls get louder for global action on silent hepatitis crisis. Lancet Infect Dis 2013, 13:657-658.
35. Shi C., Ploss A. Hepatitis C virus vaccines in the era of new direct-acting antivirals. Expert Rev Gastroenterol Hepatol 2013, 7:171-185.
36. Bichoupan K., Martel-Laferriere V., Ng M., et al. Real world costs of telaprevir-based triple therapy, including costs of managing adverse events, at the MountSinai Medical Center, NY: $195,000 per SVR12. Hepatology 2013, 58:329A-330A.
37. Evaluation of acute hepatitis C infection surveillance: United States, 2008. MMWR Morb Mortal Wkly Rep 2010, 59:1407-1410. Centers for Disease Control and Prevention.